However, we were also able to show that cTnI+ patients suffered more complications (that is, congestive heart failure; cardiogenic shock; acute kidney injury) and also received greater treatment intensity (that is, vasoactive support) compared with cTnI- patients. This evidence concerns the gene TNNI3 and Shock.